메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Medtronic to announce financial results for its first quarter o…

GALWAY, Ireland, Aug. 6, 2025 -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, August 19, 2025, for its first quarter of fiscal year 2026, which ended on Friday, July 25, 2025, A news release containing summary financial information will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com A video webcast to discuss results will begin at 7:00 a.m. CDT and can be accessed at https://investorrelations.medtronic.com Within
- 김갑성 기자
- 2025-08-06 06:21
New revolutionary brain tech platform 'ScreenIT' puts smarter…

SYDNEY, Aug. 6, 2025 -- A revolutionary new brain health assessment platform, ScreenIT, has officially launched, marking a major step forward in how brain function is monitored, assessed, and optimised across sport, healthcare, and research sectors. Developed through a close partnership between Your Brain Health (YBH) and digital innovation studio Miroma Project Factory, ScreenIT unifies over 50 brain health assessment tools into a single, intelligent platform designed to support faster, more informed decision-making around concussion, performance, and long-term brain care. Mir
- 김갑성 기자
- 2025-08-06 06:16
DeerRun Debuts 2 New Life-Changing Treadmills Designed t…

HOUSTON, Aug. 6, 2025 -- DeerRun has recently introduced two new treadmill models to its growing portfolio of fitness equipment: the Z20 Suitcase Treadmill, a Muse Design Gold Award winner, and the X20, a high-performance treadmill featuring a 15% auto incline and DeerRun's first full-length running deck. To premiere these products, DeerRun recently partnered with digital agency, Outlandish, to hold a special event where content creators and dedicated fitness individuals alike could get together and test out these game-changing products themselves. During the new product
- 김갑성 기자
- 2025-08-06 03:00
Sanyou Bio Wins the "2025 Best Customer Satisfaction CRO Awar…

SHANGHAI, Aug. 5, 2025 -- The highly anticipated 7th China Bio Innovation Expo was recently held in grand fashion in Suzhou. At the awards ceremony on August 1, Sanyou Bio was honored with the "2025 Best Customer Satisfaction CRO Award" in recognition of its deep expertise and outstanding performance in the field of preclinical research for new drug development. This prestigious award not only reflects the industry's high regard for Sanyou Bio's overall capabilities, but also serves as strong validation of the company's unwavering commitment to driving innovation in biopharmaceutica
- 김갑성 기자
- 2025-08-05 22:00
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advanc…

Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, highlights progress toward fully automated and data-driven molecular testing Introduction of CURECA™, the first fully unattended PCR automation system, and STAgora™, a real-time global data analytics platform Technologies designed to scale automation, enhance data insights, and support the company's long-term vision of a world free from diseases SEOUL, South Korea, Aug. 5, 2025 -- Seegene Inc., a global leader in molecular diagnostics, unveiled two new technologies at ADLM 2025 in Chicago (July 29–31) designed to advance
- 김갑성 기자
- 2025-08-05 21:07
Neopharma Technologies Appoints Exchange Listing to M…

NEW YORK, Aug. 5, 2025 -- Neopharma Technologies Ltd (NTL), a leading MedTech company specializing in digital drug and impairment testing for workplace and public safety, has appointed Exchange Listing, LLC to manage its upcoming U.S. initial public offering (IPO), with plans to list on the NASDAQ Stock Exchange. Neopharma has developed NEOVAULT®, the world's first integrated chain-of-custody and data management platform for point-of-care (POC) drug testing. Paired with its NEOTEST® range of regulatory-grade oral and urine screening devices, NEOVAULT® provides a sec
- 김갑성 기자
- 2025-08-05 21:00
BON Announces Reciept of Nasdaq Compliance Letter

XI'AN, China, Aug. 5, 2025 -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced reciept of compliance notification from the Nasdaq Stock Market LLC. As previously reported on a Form 6-K filed with the U.S. Securities and Exchange Commission on July 11, 2025, Bon Natural Life Limited ( "the Company") received notification from the Nasdaq Hearings Panel (the "Panel") that the Company had regained compliance with Listing
- 김갑성 기자
- 2025-08-05 21:00
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Pha…

[ 메디채널 김갑성 기자 ] • Successful validation of payloaded anti-colibactin toxin phage using IMPA™ technology • Demonstrated 'Dual-target Therapeutic Strategy' by bacterial eradication and toxin neutralization • Filed the US patent application for the candidate substance and preclinical studies including PoC underway BOSTON and SEOUL, South Korea, Aug. 5, 2025 -- Recently, a specific genotype of E. coli that may cause colorectal cancer has been detected in commonly eaten leafy vegetables such as lettuce, raising consumer concerns. Among these strains, pks+ E. coli is of particular conce
- 김갑성 기자
- 2025-08-05 20:00
Court Sides with Cardiovalve in Edwards patent spat

HANGZHOU, China, Aug. 5, 2025 -- Venus Medtech (Hangzhou) Inc. ("Venus Medtech", Stock Code: 02500.HK) recently announced a decisive legal victory for its wholly-owned subsidiary Cardiovalve Ltd. ("Cardiovalve") against Edwards Lifesciences Corporation and Edwards Lifesciences LLC. (collectively "Edwards"). The United States Court of Appeals for the Federal Circuit ("CAFC") has formally issued its mandate in Case 23-1515, affirming the Patent Trial and Appeal Board's ("PTAB") December 2022 ruling that upheld the validity of Cardiovalve's paten
- 김갑성 기자
- 2025-08-05 20:00
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Sma…

- 13-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two oral formulations of ASC30, a once-daily tablet, in 125 participants with obesity or overweight. - All 125 participants enrolled in just over one month; topline data expected in the fourth quarter of 2025. HONG KONG, Aug. 5, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today completion of enrollment in its U.S. 13-week Phase IIa study evaluating ASC30, a small molecule oral GLP-1 receptor (GLP-1R) agonist for the treatment of obesity (NCT0700290
- 김갑성 기자
- 2025-08-05 18:50

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분